Puma Biotechnology (NASDAQ:PBYI) Stock Price Passes Above Two Hundred Day Moving Average of $4.46

Puma Biotechnology, Inc. (NASDAQ:PBYI)’s stock price crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $4.46 and traded as high as $5.30. Puma Biotechnology shares last traded at $5.17, with a volume of 248,185 shares traded.

Analyst Ratings Changes

Several research analysts have recently issued reports on the stock. StockNews.com downgraded shares of Puma Biotechnology from a “buy” rating to a “hold” rating in a report on Wednesday, April 10th. HC Wainwright lowered their target price on shares of Puma Biotechnology from $8.00 to $7.00 and set a “buy” rating on the stock in a research note on Friday, March 1st.

Puma Biotechnology Stock Performance

The company has a debt-to-equity ratio of 1.23, a current ratio of 1.57 and a quick ratio of 1.50. The firm has a market cap of $241.52 million, a P/E ratio of 10.89, a PEG ratio of 2.94 and a beta of 1.28. The stock’s 50 day moving average is $5.69 and its two-hundred day moving average is $4.48.

Puma Biotechnology (NASDAQ:PBYI) last issued its quarterly earnings data on Thursday, February 29th. The biopharmaceutical company reported $0.26 earnings per share for the quarter, missing the consensus estimate of $0.33 by ($0.07). The firm had revenue of $72.20 million for the quarter, compared to the consensus estimate of $73.22 million. Puma Biotechnology had a return on equity of 58.21% and a net margin of 9.16%. As a group, equities analysts predict that Puma Biotechnology, Inc. will post 0.29 EPS for the current year.

Institutional Trading of Puma Biotechnology

Several large investors have recently added to or reduced their stakes in the company. Great Point Partners LLC acquired a new position in shares of Puma Biotechnology during the fourth quarter worth approximately $4,734,000. Marshall Wace LLP acquired a new position in shares of Puma Biotechnology during the fourth quarter worth approximately $1,359,000. Millennium Management LLC lifted its position in shares of Puma Biotechnology by 16.0% during the second quarter. Millennium Management LLC now owns 2,216,644 shares of the biopharmaceutical company’s stock worth $6,317,000 after purchasing an additional 304,969 shares in the last quarter. EAM Investors LLC acquired a new position in shares of Puma Biotechnology during the fourth quarter worth approximately $1,154,000. Finally, Citadel Advisors LLC lifted its position in shares of Puma Biotechnology by 621.1% during the second quarter. Citadel Advisors LLC now owns 299,477 shares of the biopharmaceutical company’s stock worth $853,000 after purchasing an additional 257,947 shares in the last quarter. 61.29% of the stock is owned by institutional investors.

About Puma Biotechnology

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.